Targeting HER2 in Patients With Early-Stage Disease
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in patients with early-stage breast cancer.
Clinical Pearls
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in patients with early-stage breast cancer.
- Data have shown that trastuzumab for 1 year leads to a reduction in breast cancer recurrence by about 40% and that survival improves, in relative terms, by about 40%.
- 1 year of trastuzumab (versus 6 months) proved to be a better option in a trial, though the primary endpoint of non-inferiority was not met.
- The question of duration of treatment with trastuzumab still needs to be definitively answered, but 1 year is the standard of care now.
- With respect to a non-anthracycline-based approach, the combination of weekly paclitaxel and trastuzumab has shown to be well tolerated and effective.
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
